Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

NASDAQ:SCYX - Nasdaq - US8112922005 - Common Stock - Currency: USD

1.03  +0.01 (+0.98%)

Fundamental Rating

2

SCYX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. SCYX has a bad profitability rating. Also its financial health evaluation is rather negative. SCYX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCYX had negative earnings in the past year.
In the past year SCYX has reported a negative cash flow from operations.
SCYX had negative earnings in 4 of the past 5 years.
In the past 5 years SCYX reported 4 times negative operating cash flow.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -36.79%, SCYX is in line with its industry, outperforming 46.77% of the companies in the same industry.
SCYX has a Return On Equity (-62.26%) which is in line with its industry peers.
Industry RankSector Rank
ROA -36.79%
ROE -62.26%
ROIC N/A
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCYX has been increased compared to 1 year ago.
Compared to 5 years ago, SCYX has more shares outstanding
SCYX has a better debt/assets ratio than last year.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SCYX has an Altman-Z score of -5.67. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
SCYX's Altman-Z score of -5.67 is on the low side compared to the rest of the industry. SCYX is outperformed by 67.20% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that SCYX is not too dependend on debt financing.
SCYX has a Debt to Equity ratio of 0.23. This is comparable to the rest of the industry: SCYX outperforms 42.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -5.67
ROIC/WACCN/A
WACC11.1%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

A Current Ratio of 3.13 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Current ratio (3.13) which is in line with its industry peers.
A Quick Ratio of 3.13 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Quick ratio of 3.13. This is comparable to the rest of the industry: SCYX outperforms 53.76% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

SCYX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -155.22%.
Looking at the last year, SCYX shows a very negative growth in Revenue. The Revenue has decreased by -93.70% in the last year.
Measured over the past years, SCYX shows a very strong growth in Revenue. The Revenue has been growing by 251.82% on average per year.
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-62.52%

3.2 Future

The Earnings Per Share is expected to decrease by -19.96% on average over the next years. This is quite bad
The Revenue is expected to decrease by -12.44% on average over the next years. This is quite bad
EPS Next Y-143.27%
EPS Next 2Y-46.61%
EPS Next 3Y-18.26%
EPS Next 5Y-19.96%
Revenue Next Year-90.43%
Revenue Next 2Y-33.28%
Revenue Next 3Y-2%
Revenue Next 5Y-12.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCYX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as SCYX's earnings are expected to decrease with -18.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.61%
EPS Next 3Y-18.26%

More info and screens

0

5. Dividend

5.1 Amount

SCYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (1/28/2025, 4:30:02 PM)

1.03

+0.01 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners44.65%
Inst Owner Change-0.14%
Ins Owners1.23%
Ins Owner Change0.51%
Market Cap39.09M
Analysts85.45
Price Target7.01 (580.58%)
Short Float %2.17%
Short Ratio3.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.55%
Min EPS beat(2)-45.6%
Max EPS beat(2)20.51%
EPS beat(4)2
Avg EPS beat(4)-2.83%
Min EPS beat(4)-91.18%
Max EPS beat(4)104.96%
EPS beat(8)5
Avg EPS beat(8)-1.9%
EPS beat(12)7
Avg EPS beat(12)4.62%
EPS beat(16)10
Avg EPS beat(16)0.64%
Revenue beat(2)1
Avg Revenue beat(2)37.78%
Min Revenue beat(2)-89.53%
Max Revenue beat(2)165.09%
Revenue beat(4)3
Avg Revenue beat(4)183.69%
Min Revenue beat(4)-89.53%
Max Revenue beat(4)344.25%
Revenue beat(8)6
Avg Revenue beat(8)90.61%
Revenue beat(12)6
Avg Revenue beat(12)49.19%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-899.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-44.33%
Revenue NY rev (1m)24.38%
Revenue NY rev (3m)-33.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.56
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.23
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.79%
ROE -62.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -5.67
F-Score2
WACC11.1%
ROIC/WACCN/A
Cap/Depr(3y)103.18%
Cap/Depr(5y)61.91%
Cap/Sales(3y)3.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-143.27%
EPS Next 2Y-46.61%
EPS Next 3Y-18.26%
EPS Next 5Y-19.96%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-62.52%
Revenue Next Year-90.43%
Revenue Next 2Y-33.28%
Revenue Next 3Y-2%
Revenue Next 5Y-12.44%
EBIT growth 1Y-171.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.57%
OCF growth 3YN/A
OCF growth 5YN/A